L-carnitine for acute valproic acid overdose: A systematic review of published cases

Annals of Pharmacotherapy

Volumn 44, Issue 7-8, 2010, Pages 1287-1293

  Perrott, Jerrold ^a,b   Murphy, Nancy G ^c,d,e   Zed, Peter J ^d,f,g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ROYAL COLUMBIAN HOSPITAL   (Canada)

^c IWK HEALTH CENTRE   (Canada)

^d Department of Emergency Medicine Capital Health ^*  (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

Author keywords

L carnitine; Overdose; Poisoning; Toxicology; Valproic acid

Indexed keywords

AMMONIA; CARNITINE; VALPROIC ACID; ANTICONVULSIVE AGENT; ANTIDOTE;

CLINICAL TRIAL; CONSCIOUSNESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INFUSION; DRUG OVERDOSE; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA; WHEEZING; ADULT; BLOOD; CHILD; DOSE RESPONSE;

ADULT; AMMONIA; ANTICONVULSANTS; ANTIDOTES; CARNITINE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG OVERDOSE; HUMANS; VALPROIC ACID;

EID: 77954584445     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P135     Document Type: Review

References (21)

1. Fagundes SBR. Valproic acid: review. Revista Neurosciencias 2008;16: 130-6.
2. Perucca E. Properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714.
3. Sztanjnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 2002;40:789-801. DOI 10.1081/CLT-120014645
4. Lheureux PER, Penaloza A, Zahir S, et al. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Crit Care 2005;9:431-40.
5. Bronstein AC, Spyker DA, Cantilena LR, et al. 2008 annual report of the American Association of Poison Control Centers' national poison data system (NPDS): 26th annual report. Clin Toxicol 2009;47:911-1084. DOI 10.3109/15563650903438566
6. Spiller HA, Krenzelok EP, Klein-Schwarts W, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clin Toxicol 2000;38:755-60.
7. Product monograph. Carnitor (levocarnitine). Gaithersburg, MD: Sigma- Tau Pharmaceuticals, 2004. www.carnitor.com/downloads/VIFS-6.pdf (accessed 2010 Jan 24).
8. Ishikura H, Matsuo N, Matsubara M, et al. Levels of evidence. In: Oxford Centre for Evidence Based Medicine (March 2009). Valproic acid overdose and L-carnitine therapy. J Anal Toxicol 1996;20:55-8.
9. Murakami K, Sugimoto T, Woo M, et al. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia 1996;37:687-9.
10. Houghton BL, Bowers JB. Valproic acid overdose: a case report and review of therapy. MedGenMed 2003;5(1). www.medscape.com/viewarticle/ 445062 (accessed 2010 Jan 24).
11. Minville V, Roche Tissot C, Samii K. Haemodialysis, L-carnitine therapy and valproic acid overdose. [French, translated with Google Translate] Ann Fr Anesth Reanim 2004;23:357-60. DOI 10.1016/j.annfar.2003.11.018
12. Chan YC, Tse ML, Lau FL. Two cases of valproic acid poisoning treated with L-carnitine. Hum Exp Toxicol 2007;26:967-9. DOI 10.1177/0960327107087799
13. Sikma MA, Mier JC, Meulenbelt J. Massive valproic acid overdose, a misleading case. Am J Emerg Med 2008;26:110e3-6. DOI 10.1016/j.ajem.2007.06.020
14. Jung J, Ahn K. A case of hemoperfusion and L-carnitine management in valproic acid overdose. Am J Emerg Med 2008;26:388e3-4. DOI 10.1016/j.ajem.2007. 07.032
15. LoVecchio F, Shriki J, Samaddar R. L-Carnitine was safely administered in the setting of valproate toxicity. Am J Emerg Med 2005;23:321-2. DOI 10.1016/j.ajem.2005.02.015
16. Brass EP, Adler S, Sietsema KE, et al. Intravenous L-carnitine increases carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 2001;37:1018-28. DOI 10.1053/ajkd.2001.23647
17. Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage 2006;32:551-9. DOI 10.1016/j.jpainsymman.2006.09.001
18. Arduini A, Bonomini M, Savica V, et al. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 2008;120: 149-56. DOI 10.1016/j.pharmthera.2008.08.008
19. Goldfrank LR, Nelson LS, Howland MA, Lewin NA, Flomenbaum NE, Hoffman RS, eds. Goldfrank's toxicologic emergencies. 8th ed. New York: McGraw-Hill, 2006.
20. Olsen KR, Benowitz NL, Blanc PD, eds. Poisoning and drug overdose. 5th ed. New York: McGraw-Hill, 2006.
21. Centre for evidence based medicine. www.cebm.net/index.aspx?o=1025 (accessed 2010 Jan 20).